Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-062440
Filing Date
2023-11-13
Accepted
2023-11-13 07:33:52
Documents
69
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q akro-20230930.htm   iXBRL 10-Q 3379406
2 EX-31.1 akro-ex31_1.htm EX-31.1 18122
3 EX-31.2 akro-ex31_2.htm EX-31.2 17802
4 EX-32.1 akro-ex32_1.htm EX-32.1 15806
  Complete submission text file 0000950170-23-062440.txt   11904044

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akro-20230930_def.xml EX-101.DEF 229313
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akro-20230930_cal.xml EX-101.CAL 45890
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akro-20230930_pre.xml EX-101.PRE 394500
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akro-20230930_lab.xml EX-101.LAB 526520
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akro-20230930.xsd EX-101.SCH 61348
63 EXTRACTED XBRL INSTANCE DOCUMENT akro-20230930_htm.xml XML 2444150
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38944 | Film No.: 231395123
SIC: 2834 Pharmaceutical Preparations